A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs.
Sang Gyun Kim, Tae-Oh Kim, Sung Woo Jung, Byung-Hoon Min, Jung-Hwan Oh, Hyun-Soo Kim, Gil Ho Lee, Ji Hyun Song, In Kyung Sung, Young Sin Cho, Suck Chei Choi, Yun Jeong Lim, Byung-Wook Kim, Cheol Min Shin, Cheal Wung Huh, Ji Won Kim, Kyung-Oh Kim, Yu Kyung Cho, Oh Young Lee, Jeong Seop Moon, Hyun Woo Lee, Hwoon-Yong Jung, Woon Geon Shin, Jae-Gyu Kim, Ju Yup Lee, Su Jung Han, Sang-Wook Kim, Joon Hyun Cho, Hyun Lim, Tae Ho Kim, Moo In Park, Gwang Ho Baik, Ra Ri Cha, Sang Kil Lee, Jae J Kim
Gut Liver 20(4) 551-561
摘要
摘要
BACKGROUND/AIMS: Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk of peptic ulcers. Tegoprazan, a novel potassium-competitive acid blocker, provides rapid and potent inhibition of acid production. This study evaluated whether tegoprazan 25 mg is non-inferior to lansoprazole 15 mg in preventing NSAID-induced peptic ulcer. METHODS: In this double-blind, randomized, active-controlled, multicenter phase III trial, patients requiring NSAIDs for up to 24 weeks were randomized (1:1) to the tegoprazan or the lansoprazole group. The primary endpoint was the incidence of peptic ulcer at week 24 in the per-protocol population. Secondary endpoints were NSAID-induced gastrointestinal symptom-free rates. Safety outcomes included adverse drug reactions (ADRs) and serious adverse events (SAEs). RESULTS: A total of 392 patients were randomized, and 269 patients were analyzed in the perprotocol set. Tegoprazan was non-inferior to lansoprazole for the prevention of gastroduodenal ulcers (p=0.0004). The heartburn-free rate at week 12 was higher in the tegoprazan group (p=0.0421), while other symptom-free rates did not differ significantly. In terms of safety, ADR and SAE rates were comparable and not significantly different. CONCLUSIONS: Tegoprazan was non-inferior to lansoprazole in preventing NSAID-induced peptic ulcers with excellent tolerance. Tegoprazan represents a clinically effective alternative gastroprotective therapy (ClinicalTrials.gov identifier NCT04840550).
KM 提取结果
0 个 Figure · 0 个 KM 面板